BioCentury
ARTICLE | Clinical News

Aimspro regulatory update

March 10, 2014 7:00 AM UTC

Daval said FDA granted Orphan Drug designation to Aimspro to treat systemic sclerosis. The anti-inflammatory agent derived from hyperimmune caprine serum has completed a Phase II trial to treat late-s...